Report
par
Public Health Ontario
Date de publication
2017
Géographie
Canada
Langue de la ressource
English
Texte disponible en version intégrale
Oui
Open Access / OK to Reproduce
Non
Évalué par des pairs
No
L’objectif
This Evidence Brief asks: What is the evidence of effectiveness of supervised injectable opioid agonist treatment with diacetylmorphine (DAM) or hydromorphone (HDM) on treatment retention (i.e., individual remaining on treatment), drug use, social, health or other outcomes among people with opioid use disorder compared to patients using another treatment or no treatment?
Constatations/points à retenir
- siOAT has been studied primarily among patients who have undergone methadone treatment in the past.
- siOAT trials have demonstrated significant benefits for retention in treatment, reducing the use of street drugs, and reducing illegal activities in this population.
- siOAT is associated with a greater number of serious adverse events compared with methadone, but these can be managed in a supervised setting.
- Hydromorphone is as effective as diacetylmorphine for siOAT, with fewer adverse events.
Mots clés
Evidence base
Safer supply
